YBGJ (Yubo International Biotech) ROC %: -178.40% (As of Mar. 2026)

What is Yubo International Biotech ROC %?

Yubo International Biotech YBGJ +30.43% ROC % is -178.40% as of Mar. 2026. The stock has 2 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Yubo International Biotech's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -178.40%.

As of today (2026-06-28), Yubo International Biotech's WACC % is 23.32%. Yubo International Biotech's ROC % is -132.38% (calculated using TTM income statement data). Yubo International Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Yubo International Biotech (OTCPK:YBGJ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Yubo International Biotech's WACC % is 23.32%. Yubo International Biotech's ROC % is -132.38% (calculated using TTM income statement data). Yubo International Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Yubo International Biotech ROC % Related Terms

Yubo International Biotech ROC % Historical Data

* Premium members only.

The historical data trend for Yubo International Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yubo International Biotech ROC % Chart

Yubo International Biotech Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROC %

Get a 7-Day Free Trial

-48.22

-33.29

-58.14

-107.40

-101.45

Yubo International Biotech Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROC %	Get a 7-Day Free Trial															-135.71	-94.74	-132.06	-144.85	-178.40

Yubo International Biotech ROC % Calculation

Yubo International Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2025 is calculated as:

	ROC % (A: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Dec. 2024 )	+	Invested Capital (A: Dec. 2025 ))	/ count )
=	-1.188 * ( 1 - 0% )	/	( (1.644	+	0.698)	/ 2 )
=	-1.188	/	1.171
=	-101.45 %

where

	Invested Capital		(A: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.535	-	3.93	-	( 0.007	-	max(0, 4.722	-	0.683	+	0.007	))
=	1.644

	Invested Capital		(A: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.847	-	2.272	-	( 0.008	-	max(0, 2.791	-	0.668	+	0.008	))
=	0.698

Yubo International Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-1.156 * ( 1 - 0% )	/	( (0.698	+	0.598)	/ 2 )
=	-1.156	/	0.648
=	-178.40 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.847	-	2.272	-	( 0.008	-	max(0, 2.791	-	0.668	+	0.008	))
=	0.698

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.71	-	2.533	-	( 0.01	-	max(0, 3.019	-	0.598	+	0.01	))
=	0.598

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

Frequently Asked Questions Learn more about ROC % →

What does a ROC % of -178.40% mean?

Yubo International Biotech (YBGJ) has a ROC % of -178.40% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Yubo International Biotech and its competitors.

Is Yubo International Biotech's ROC % too high?

Yubo International Biotech's current ROC % is -178.40%.

How does Yubo International Biotech's ROC % compare to ECIA and GCTK?

Yubo International Biotech's ROC % of -178.40% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROC % is 1.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROC % for a Medical Devices & Instruments company?

The median ROC % among Medical Devices & Instruments companies is 1.26, based on 848 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROC % mean?

A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Yubo International Biotech and its competitors. For the Medical Devices & Instruments industry, the median ROC % is 1.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yubo International Biotech's current ROC % is -178.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Yubo International Biotech stock overvalued right now?

Yubo International Biotech (YBGJ) has a current ROC % of -178.40%. The current ROC % is -178.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROC % calculated?

ROC % is calculated from a company's financial statements. For Yubo International Biotech (YBGJ), the current ROC % is -178.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yubo International Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies ECIA GCTK RSCF CBSC NXGL CUPR LUCY ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST TSE:4543 XPAR:DIM XSWX:STMN XTER:SRT OCSE:COLO B

Address No. 10 Chaoyang Park South Road, Room 1102, 11th Floor, Building 2, Chaoyang District, Beijing, CHN, 100026

Website http://www.yubogroup.com

Yubo International Biotech Ltd is a technology company focused on the research, development, and application of endometrial stem cells. It offers products and services under the brand VIVCELL. Its product offerings include healthcare products for the respiratory system, skincare products, hair care products, healthy beverages and male and female personal care products. It also offers stem cell-related services including cell testing and health management consulting services. The company derives its revenue from the sale of certain health management services and the sale of nebulizers containing frozen tubes with medical fluid. The nebulizers are sold directly to consumers on its online e-commerce platform.